Nemolizumab is safe and effective for long-term use in patients with moderate-to-severe atopic dermatitis, an extension study shows.

Eli Lilly has signed a licensing deal with Cipla to market its blockbuster weight-loss drug under the brand name Yurpeak in ...

By Bhanvi Satija and Ludwig Burger FRANKFURT (Reuters) -Shares of Swiss drugmaker Roche fell on Thursday after sales of its ...

Eli Lilly has teamed up with Cipla to market its popular weight-loss drug Mounjaro in India. The medication, which is used ...

Eli Lilly and Company is a Strong Buy due to strong growth in obesity and diabetes drugs and pipeline innovation. Learn more ...

Under the agreement, Cipla will market the drug under a new brand name, Yurpeak, while Lilly continues to sell it as Mounjaro ...

Indian drugmaker Cipla signed an agreement with Eli Lilly to sell tirzepatide, the active ingredient in the US company's blockbuster weight-loss drug Mounjaro, in India, the companies said on Thursday ...

Under this strategic arrangement, Cipla will distribute and promote Yurpeak, marking the second brand of tirzepatide to be ...

Eli Lilly signed an agreement with Cipla, allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

The evening was a stunning blend of tradition and grandeur, with décor and styling inspired by Sanjay Leela Bhansalis ...

Indian drugmaker Cipla signed an agreement with Eli Lilly to sell tirzepatide, the active ingredient in the U.S. company’s weight-loss drug Mounjaro, in India, the companies announced on Thursday.

By Ludwig Burger and Bhanvi Satija FRANKFURT (Reuters) -Swiss drugmaker Roche on Thursday lifted its full-year profit ...